Jiawei Zhao

Jiawei Zhao

Auto-generated profile, based on publicly available information

Jiawei Zhao

Harvard Medical School

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Science
Verified
Journal Article
Closed access
JZJiawei Zhao
Jiawei Zhao
ACAndy Q. Chen
Andy Q. Chen
JRJaewook Ryu
Jaewook Ryu
JMJosefina del Mármol
Josefina del Mármol
Most insects, including human-targeting mosquitoes, detect odors through odorant-activated ion channel complexes consisting of a divergent odorant-binding subunit (OR) and a conserved co-receptor subunit (Orco). As a basis for understanding how odorants activate these heteromeric receptors, we report here cryo–electron microscopy structures of two different heteromeric odorant receptor complexes containing ORs from disease-vector mosquitos Aedes aegypti or Anopheles gambiae . These structures reveal an unexpected stoichiometry of one OR to three Orco subunits. Comparison of structures in odorant-bound and unbound states indicates that odorant binding to the sole OR subunit is sufficient to open the channel pore, suggesting a mechanism of OR activation and a conceptual framework for understanding evolution of insect odorant receptor sensitivity.

10 April 2024 in Nature
Verified
Journal Article
Open access
PDF file
JZJiawei Zhao
Jiawei Zhao
MEMatthias Elgeti
Matthias Elgeti
EOEvan S. O’bRien
Evan S. O’bRien
CSCecília P. Sár
Cecília P. Sár
ADAmal Ei Daibani
Amal Ei Daibani
CCChunlai Chen
Chunlai Chen
The µ-opioid receptor (µOR) is an important target for pain management1 and molecular understanding of drug action on µOR will facilitate the development of better therapeutics. Here we show, using double electron–electron resonance and single-molecule fluorescence resonance energy transfer, how ligand-specific conformational changes of µOR translate into a broad range of intrinsic efficacies at the transducer level. We identify several conformations of the cytoplasmic face of the receptor that interconvert on different timescales, including a pre-activated conformation that is capable of G-protein binding, and a fully activated conformation that markedly reduces GDP affinity within the ternary complex. Interaction of β-arrestin-1 with the μOR core binding site appears less specific and occurs with much lower affinity than binding of Gi.

10 July 2020 in Science
Verified
Journal Article
Closed access
SMShoji Maeda
Shoji Maeda
JXJun Xu
Jun Xu
FKFrancois Marie Ngako Kadji
Francois Marie Ngako Kadji
MCMary J. Clark
Mary J. Clark
JZJiawei Zhao
Jiawei Zhao
BKBrian K. Kobilka
Brian K. Kobilka
Engineering a toxin: Developing drugs that target a specific subtype in a G protein–coupled receptor (GPCR) family is a major challenge. Maeda et al. examined the basis of specificity of a snake venom toxin binding to muscarinic acetylcholine receptors (MAChRs), which mediate many functions of the central and parasympathetic nervous systems. They determined a structure that shows why the mamba venom toxin MT7 is specific for one receptor, M 1 AChR, and also explains how it inhibits downstream signaling. Based on this structure, they engineered MT7 to be selective for another receptor, M 2 AChR, instead of M 1 ChR. The toxin may present a promising scaffold for developing specific GPCR modulators. Science , this issue p. 161

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
YTYouqi Tao
Youqi Tao
JXJingfei Xie
Jingfei Xie
QZQinglu Zhong
Qinglu Zhong
YWYongyao Wang
Yongyao Wang
SZShengnan Zhang
Shengnan Zhang
CLCong Liu
Cong Liu
The protein tyrosine phosphatase SHP2 mediates multiple signal transductions in various cellular pathways, controlled by a variety of upstream inputs. SHP2 dysregulation is causative of different types of cancers and developmental disorders, making it a promising drug target. However, how SHP2 is modulated by its different regulators remains largely unknown. Here, we use single-molecule fluorescence resonance energy transfer (smFRET) and molecular dynamics (MD) simulations to investigate this question. We identify a partially-open, semi-active conformation of SHP2 that is intermediate between the known open and closed states. We further demonstrate a "multiple gear" regulatory mechanism, in which different activators (e.g. IRS-1 and CagA), oncogenic mutations (e.g. E76A) and allosteric inhibitors (e.g. SHP099) can shift the equilibrium of the three conformational states and regulate SHP2 activity to different levels. Our work reveals the essential role of the intermediate state in fine-tuning the activity of SHP2, which may provide new opportunities for drug development for relevant cancers.

4 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
XZXin Zhang
Xin Zhang
KGKaixuan Gao
Kaixuan Gao
JNJia Nie
Jia Nie
HMHengyu Meng
Hengyu Meng
XSXiaoou Sun
Xiaoou Sun
XLXiangyu Liu
Xiangyu Liu
G protein–coupled receptors (GPCRs) are prominent drug targets that have attracted intensive efforts in drug screening. Binding-based screening methods for GPCR ligands often require conformationally stable, purified receptors. However, obtaining large quantities of GPCRs in stable states, particularly with unoccupied extracellular ligand-binding pockets and especially in their active conformations, remains challenging due to the inherent dynamic nature of these receptors. To address this challenge, we propose a universal approach for stabilizing GPCRs in specific conformations. Using the M1 muscarinic acetylcholine receptor (M1R) as a model, we successfully stabilized M1R in its active conformation through de novo design of a fusion protein, and further demonstrated the generalizability of this strategy by applying it to other GPCRs. We screened a synthetic yeast display library of nanobodies against both the stabilized active-state and previously reported inactive-state M1R, identifying several nanobodies that specifically recognize each conformation. This method not only facilitates the stabilization of GPCRs in desired states but also provides valuable tools for developing more selective therapeutic agents, enhancing drug discovery efficiency and specificity.

29 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JZJiawei Zhao
Jiawei Zhao
MEMatthias Elgeti
Matthias Elgeti
EOEvan S. O’brien
Evan S. O’brien
CSCecília P. Sár
Cecília P. Sár
ADAmal Ei Daibani
Amal Ei Daibani
CCChunlai Chen
Chunlai Chen
The μ-opioid receptor (μOR) is an important target for pain management and the molecular understanding of drug action will facilitate the development of better therapeutics. Here we show, using double electron-electron resonance (DEER) and single-molecule fluorescence resonance energy transfer (smFRET), how ligand-specific conformational changes of the μOR translate into a broad range of intrinsic efficacies at the transducer level. We identify several cytoplasmic receptor conformations interconverting on different timescales, including a pre-activated receptor conformation which is capable of G protein binding, and a fully activated conformation which dramatically lowers GDP affinity within the ternary complex. Interaction of β-arrestin-1 with the μOR core binding site appears less specific and occurs with much lower affinity than binding of G protein G i . One-Sentence Summary: Ligand-dependent conformational dynamics of the μ-opioid receptor determine downstream signaling efficacy.